Phase 3 N=247 Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: The Changes in HbA1c at Week 24 — -0.72; -0.01 percentage of HbA1c
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=5,920 Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)
Malaria,Falciparum · Children, Only
Primary: Incidence of Clinical Episodes of Malaria — 304.8; 278.2; 113.3 No. of events/1000 person years at risk
Phase 3 N=254 Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.95; -0.14 percentage of HbA1c
Phase 3 N=47 Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
Primary Immunodeficiency Disease
Primary: Incidence Rate of Acute Serious Bacterial Infections (ABSIs) — 0.0; 0.0 infections per participant-year
Phase 3 N=642 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 24.1; 56.9; 63.8 percentage of participants — p=<0.0001
Phase 3 N=1,705 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 36.2; 65.0; 70.6; 78.5 percentage of participants — p=<0.0001
Phase 3 N=751 A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 — 0.09; 0.06 percentage of HbA1c — p=0.783
Phase 3 N=372 Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
COVID-19
Primary: Proportion of Responders in Each Treatment Group — 88; 98; 87 Participants — p=0.434
Phase 3 N=96 Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants in Phase 2 With Anesthesia Success — 38; 4; 2; 16 participants
Phase 3 N=2,023 Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1760; 98; 617; 27 Participants
Phase 3 N=18 Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Type 1 Diabetes
Primary: Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study — 4.65; 3.67; 8.8; 9.05 mg/kg*minute*microIU/mL*100
Phase 3 N=158 THINC-it Vortioxetine - Sensitivity to Change
Major Depressive Disorder · Cognitive Change
Primary: Cognition Measured Using the THINC-it Tool — -0.05; -0.12; 0.12; 0 z-score
Phase 3 N=65 Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Oropharynx Cancer
Primary: Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up — 20.1; 29.1…
Phase 3 N=152 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16 — 43.7 percentage of participants
Phase 3 N=1,444 A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.20; -2.37; -1.34 Percentage of HbA1c — p=<0.001